Valganciclovir

Transplantation Reviews

Volumn 20, Issue 2, 2006, Pages 82-87

  Pescovitz, Mark D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG STRUCTURE; FOOD DRUG INTERACTION; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEUTROPENIA; RETINITIS; VIREMIA;

EID: 33746053475     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.05.003     Document Type: Article

References (57)

1. Patel R., Snydman D.R., Rubin R.H., et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61 (1996) 1279-1289
2. Kanj S.S., Sharara A.I., Clavien P.A., and Hamilton J.D. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 22 (1996) 537-549
3. Conti D.J., Freed B.M., Gruber S.A., and Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg 129 (1994) 443-447
4. Balfour J., Henry H., Chace B.A., Stapleton J.T., Simmons R.L., and Fryd D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320 (1989) 1381-1388
5. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340 (1999) 1462-1470
6. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350 (1997) 1729-1733
7. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
8. Singh N., Yu V.L., Mieles L., Wagner M.M., Miner R.C., and Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 120 (1994) 375-381
9. Matthews T., and Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10 Suppl 3 (1988) S490-S494
10. Crumpacker C.S. Ganciclovir. N Engl J Med 335 (1996) 721-729
11. Hodson E.M., Jones C.A., Webster A.C., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365 (2005) 2105-2115
12. Lipson S.M., Tseng L.F., Kaplan M.H., and Biond F.X. Antiviral susceptibility testing of cytomegalovirus from primary culture using shell vial assay to detect the late viral antigen. Diagn Microbiol Infect Dis 17 (1993) 283-291
13. Boivin G., Erice A., Crane D.D., Dunn D.L., and Balfour Jr. H.H. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 168 (1993) 332-335
14. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12 (1999) 286-297
15. Chou S., Lurain N.S., Thompson K.D., Miner R.C., and Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 188 (2003) 32-39
16. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., and Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185 (2002) 20-27
17. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
18. Martin D.F., Sierra-Madero J., Walmsley S., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346 (2002) 1119-1126
19. Razonable R.R., Brown R.A., Humar A., Covington E., Alecock E., and Paya C.V. Herpes virus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 192 (2005) 1331-1339
20. Funch D.P., Walker A.M., Schneider G., Zihyadeh N., and Pescovitz M.D. Ganciclovir/acyclovir reduce the risk of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
21. Pescovitz M.D., Pruett T.L., Gonwa T., et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 66 (1998) 1104-1107
22. Jung D., and Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39 (1999) 800-804
23. Lee V.H. Membrane transporters. Eur J Pharm Sci 311 Suppl 2 (2000) S41-S50
24. Ganapathy M.E., Huang W., Wang H., Ganapathy V., and Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 19 (1998) 470-475
25. Sinko P.J., and Balimane P.V. Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 19 (1998) 209-217
26. Pescovitz M.D. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpl Infect Dis 1 (1999) 31-34
27. Ciancio G., Burke G.W., Mattiazzi A., et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 18 (2004) 402-406
28. Park J.M., Lake K.D., Arenas J.D., and Fontana R.J. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 12 (2005) 112-116
29. Jain A., Orloff M., Kashyap R., et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?. Transplant Proc 37 (2005) 3182-3186
30. Boivin G., Goyette N., Gilbert C., et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 189 (2004) 1615-1618
31. Boivin G., Goyette N., Gilbert C., and Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 77 (2005) 425-429
32. Winston D.J., Winn D., Shaked A., and Busuttil R.W. Randomized comparison of ganciclovir and high-dose acyclovir to prevent cytomegalovirus for long term-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 346 (1995) 43-50
33. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 4 (2004) 644-649
34. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 5 (2005) 1065-1070
35. Keven K., Basu A., Tan H.P., et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 36 (2004) 3107-3112
36. Gabardi S., Magee C.C., Baroletti S.A., Powelson J.A., Cina J.L., and Chandraker A.K. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 24 (2004) 1323-1330
37. Taber D.J., Ashcraft E., Baillie G.M., et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 6 (2004) 101-109
38. Akalin E., Sehgal V., Ames S., et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3 (2003) 731-735
39. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 (2004) 1635-1642
40. Gruber S.A., Garnick J., Morawski K., et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 19 (2005) 273-278
41. Wiltshire H., Hirankarn S., Farrell C., et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 44 (2005) 495-507
42. Wiltshire H., Paya C.V., Pescovitz M.D., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79 (2005) 1477-1483
43. Anaizi N.H., Dentinger P.J., and Swenson C.F. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 59 (2002) 1267-1270
44. Clark B.S., Chang I.F., Karpen S.J., et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 77 (2004) 1480
45. Danziger-Isakov L.A., Faro A., Sweet S., et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs. Pediatr Transplant 7 (2003) 469-473
46. Singh N., Wannstedt C., Keyes L., Gayowski T., Wagener M.M., and Cacciarelli T.V. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 (2005) 85-90
47. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 35 (2006) 474-477
48. Diaz-Pedroche C., Lumbreras C., Del Valle P., et al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant Proc 37 (2005) 3766-3767
49. Aigner C., Jaksch P., Winkler G., et al. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Wien Klin Wochenschr 117 (2005) 480-484
50. Zamora M.R., Davis R.D., and Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80 (2005) 157-163
51. Ayala E., Greene J., Sandin R., et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37 (2006) 851-856
52. Humar A., Siegal D., Moussa G., and Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 192 (2005) 1154-1157
53. Fellay J., Venetz J.P., Aubert J.D., Seydoux C., Pascual M., and Meylan P.R. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 37 (2005) 949-951
54. Babel N., Gabdrakhmanova L., Juergensen J.S., et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 78 (2004) 283-285
55. Kalpoe J.S., Schippers E.F., Eling Y., Sijpkens Y.W., de Fijter J.W., and Kroes A.C. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir Ther 10 (2005) 119-123
56. Schleiss M.R., and Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4 (2005) 381-406
57. Ma J.D., Nafziger A.N., Villano S.A., Gaedigk A., and Bertino Jr. J.S. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 50 (2006) 1130-1135